Estrogen-related receptor alpha and cancer: axis of evil

References

• Benoit G, Cooney A, Giguere V, et al. International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev 2006;58:798–836
   PubMed Web of Science ®Google Scholar
• Giguère V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev 2008;29:677–96
   PubMed Web of Science ®Google Scholar
• Ranhotra HS. The estrogen-related receptor α: the oldest, yet an energetic orphan with robust biological functions. J Recept Signal Transduct Res 2010;30:193–205
   PubMed Web of Science ®Google Scholar
• Ochnik AM, Yee D. Estrogen-related receptor alpha: an orphan finds a family. Breast Cancer Res 2012;14:309–10
   PubMed Web of Science ®Google Scholar
• Chang CY, McDonnell DP. Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer. Clin Cancer Res 2012;18:6089–95
   PubMed Web of Science ®Google Scholar
• Cavallini A, Notarnicola M, Giannini R, et al. Oestrogen receptor-related receptor α (ERRα) and oestrogen receptors (ERα and ERβ) exhibit different gene expression in human colorectal tumour progression. Eur J Cancer 2005;41:1487–94
   PubMed Web of Science ®Google Scholar
• Sun P, Sehouli J, Denkert C, et al. Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J Mol Med 2005;83:457–67
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Jordan VC. Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr Top Med Chem 2006;6:203–15
   PubMed Web of Science ®Google Scholar
• Deblois G, St-Pierre J, Giguère V. The PGC-1/ERR signaling axis in cancer. Oncogene 2013;32:3483–90
   PubMed Web of Science ®Google Scholar
• Zou C, Yu S, Xu Z, et al. ERRα augments HIF-1 signalling by directly interacting with HIF-1α in normoxic and hypoxic prostate cancer cells. J Pathol 2014;233:61–73
   PubMed Web of Science ®Google Scholar
• Bernatchez G, Giroux V, Lassalle T, et al. ERRα metabolic nuclear receptor controls growth of colon cancer cells. Carcinogenesis 2013;34:2253–61
   PubMed Web of Science ®Google Scholar
• Mirebeau-Prunier D, Le Pennec S, Jacques C, et al. Estrogen-related receptor alpha modulates lactate dehydrogenase activity in thyroid tumors. PLoS One 2013;8:e58683
   PubMed Web of Science ®Google Scholar
• Stein RA, Chang CY, Kazmin DA, et al. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res 2008;68:8805–12
   PubMed Web of Science ®Google Scholar
• Jarzabek K, Koda M, Kozlowski L, et al. The significance of the expression of ERRalpha as a potential biomarker in breast cancer. J Steroid Biochem Mol Biol 2009;113:127–33
   PubMed Web of Science ®Google Scholar
• Heck S, Rom J, Thewes V, et al. Estrogen-related receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma. Cancer Res 2009;69:5186–93
   PubMed Web of Science ®Google Scholar
• Stein RA, Gaillard S, McDonnell DP. Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. J Steroid Biochem Mol Biol 2009;114:106–12
   PubMed Web of Science ®Google Scholar
• Fradet A, Sorel H, Bouazza L, et al. Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res 2011;71:5728–38
   PubMed Web of Science ®Google Scholar
• Li Y, Birnbaumer L, Teng CT. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol 2010;24:969–80
   PubMed Web of Science ®Google Scholar
• Chang CY, Kazmin D, Jasper JS, et al. The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell 2011;20:500–10
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li Y, Lou G, et al. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One 2012;7:e39102
   PubMed Web of Science ®Google Scholar
• May FE. Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer. Cancer Manage Res 2014;6:225–52
   PubMed Web of Science ®Google Scholar
• Thewes V, Simon R, Schroeter P, et al. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer. Cancer Res 2015;75:720–31
   PubMed Web of Science ®Google Scholar
• Duellman SJ, Calaoagan JM, Sato BG, et al. A novel steroidal inhibitor of estrogen-related receptor alpha (ERR alpha). Biochem Pharmacol 2010;80:819–26
   PubMed Web of Science ®Google Scholar
• Chao WR, Amin K, Shi YH, et al. SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo. Angiogenesis 2011;14:1–16
   PubMed Web of Science ®Google Scholar
• Fujimoto J, Alam SM, Jahan I, et al. Clinical implication of estrogen-related receptor (ERR) expression in ovarian cancers. J Steroid Biochem Mol Biol 2007;104:301–4
   PubMed Web of Science ®Google Scholar
• Salzman J, Marinelli RJ, Wang PL, et al. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol 2011;9:e1001156
   PubMed Web of Science ®Google Scholar
• Micci F, Panagopoulos I, Thorsen J, et al. Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas. PLoS Biol 2014;12:e1001784
   PubMed Web of Science ®Google Scholar
• Ramchandani D, Weber GF. Interactions between osteopontin and vascular endothelial growth factor: Implications for cancer. Biochim Biophys Acta 2015;1855:202–22
   PubMed Web of Science ®Google Scholar
• Boudjadi S, Bernatchez G, Beaulieu JF, et al. Control of the human osteopontin promoter by ERRα in colorectal cancer. Am J Pathol 2013;183:266–76
   PubMed Web of Science ®Google Scholar
• Fujimura T, Takahashi S, Urano T, et al. Increased expression of estrogen-related receptor alpha (ERRalpha) is a negative prognostic predictor in human prostate cancer. Int J Cancer 2007;120:2325–30
   PubMed Web of Science ®Google Scholar